{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T01:51:53Z","timestamp":1774749113758,"version":"3.50.1"},"reference-count":33,"publisher":"Impact Journals, LLC","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2020,5,26]]},"DOI":"10.18632\/oncotarget.27586","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T15:07:30Z","timestamp":1590505650000},"page":"1929-1941","source":"Crossref","is-referenced-by-count":19,"title":["An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma"],"prefix":"10.18632","volume":"11","author":[{"given":"Katherine M.","family":"Bever","sequence":"first","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA"},{"name":"Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA"},{"name":"The Skip Viragh Center for Pancreas Cancer at Johns Hopkins, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erkut H.","family":"Borazanci","sequence":"additional","affiliation":[{"name":"Virginia Piper Cancer Center at HonorHealth, Scottsdale, AZ, USA"},{"name":"Molecular Medicine Division, Translational Genomics Research Institute (TGen), Phoenix, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA"},{"name":"Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer N.","family":"Durham","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA"},{"name":"Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Pinero","sequence":"additional","affiliation":[{"name":"Virginia Piper Cancer Center at HonorHealth, Scottsdale, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayle S.","family":"Jameson","sequence":"additional","affiliation":[{"name":"Virginia Piper Cancer Center at HonorHealth, Scottsdale, AZ, USA"},{"name":"Molecular Medicine Division, Translational Genomics Research Institute (TGen), Phoenix, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber","family":"Vrana","sequence":"additional","affiliation":[{"name":"Virginia Piper Cancer Center at HonorHealth, Scottsdale, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meizheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA"},{"name":"Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara","family":"Wilt","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA"},{"name":"Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA"},{"name":"The Skip Viragh Center for Pancreas Cancer at Johns Hopkins, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie A.","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA"},{"name":"Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA"},{"name":"The Skip Viragh Center for Pancreas Cancer at Johns Hopkins, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA"},{"name":"Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA"},{"name":"Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA"},{"name":"Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafu","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai City, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey P.","family":"Leal","sequence":"additional","affiliation":[{"name":"The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana De","family":"Jesus-Acosta","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA"},{"name":"The Skip Viragh Center for Pancreas Cancer at Johns Hopkins, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA"},{"name":"Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA"},{"name":"The Skip Viragh Center for Pancreas Cancer at Johns Hopkins, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Laheru","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA"},{"name":"Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA"},{"name":"The Skip Viragh Center for Pancreas Cancer at Johns Hopkins, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel D.","family":"Von Hoff","sequence":"additional","affiliation":[{"name":"Virginia Piper Cancer Center at HonorHealth, Scottsdale, AZ, USA"},{"name":"Molecular Medicine Division, Translational Genomics Research Institute (TGen), Phoenix, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Jaffee","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA"},{"name":"Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA"},{"name":"The Skip Viragh Center for Pancreas Cancer at Johns Hopkins, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D.","family":"Powell","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA"},{"name":"Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dung T.","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA"},{"name":"Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA"},{"name":"The Skip Viragh Center for Pancreas Cancer at Johns Hopkins, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Jemal","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Khemissa-Akouz","year":"2011","journal-title":"N Engl J Med"},{"key":"3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Dowden","year":"2013","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1200\/JCO.2018.36.15_suppl.4000","article-title":"FOLFIRINOX until progression, FOLRIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX)","volume":"36","author":"Turpin","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Alg\u00fcl","year":"2019","journal-title":"N Engl J Med"},{"key":"6","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1136\/gutjnl-2014-307616","article-title":"A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras\/Mek\/Erk-induced hyperactive mTOR signalling","volume":"65","author":"Beckers","year":"2016","journal-title":"Gut"},{"key":"7","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1136\/gutjnl-2013-306202","article-title":"Targeting mTOR dependency in pancreatic cancer","volume":"63","author":"Carter","year":"2014","journal-title":"Gut"},{"key":"8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11010-009-0154-x","article-title":"PTEN regulates angiogenesis through PI3K\/Akt\/VEGF signaling pathway in human pancreatic cancer cells","volume":"331","author":"Takeyama","year":"2009","journal-title":"Mol Cell Biochem"},{"key":"9","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jss.2012.05.065","article-title":"Akt\/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells","volume":"178","author":"Miyazaki","year":"2012","journal-title":"J Surg Res"},{"key":"10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08155","article-title":"mTOR regulates memory CD8 T-cell differentiation","volume":"460","author":"Ahmed","year":"2009","journal-title":"Nature"},{"key":"11","doi-asserted-by":"publisher","first-page":"e0121710","DOI":"10.1371\/journal.pone.0121710","article-title":"Cellular size as a means of tracking mTOR activity and cell fate of CD4+ T cells upon antigen recognition","volume":"10","author":"Powell","year":"2015","journal-title":"PLoS One"},{"key":"12","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.celrep.2015.12.095","article-title":"Mammalian Target of Rapamycin Complex 2 Controls CD8 T Cell Memory Differentiation in a Foxo1-Dependent Manner","volume":"14","author":"Romero","year":"2016","journal-title":"Cell Rep"},{"key":"13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.4049\/jimmunol.1701477","article-title":"mTOR Complex 1 Signaling Regulates the Generation and Function of Central and Effector Foxp3(+) Regulatory T Cells","volume":"201","author":"Powell","year":"2018","journal-title":"J Immunol"},{"key":"14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/1471-2407-10-368","article-title":"Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies","volume":"10","author":"Abbruzzese","year":"2010","journal-title":"BMC Cancer"},{"key":"15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.2008.18.9514","article-title":"Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer","volume":"27","author":"Fuchs","year":"2009","journal-title":"J Clin Oncol"},{"key":"16","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s11523-018-0605-y","article-title":"Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I\/II Study","volume":"13","author":"Goudopoulou","year":"2018","journal-title":"Target Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2174\/1568009614666141020105502","article-title":"Anti-diabetic drug metformin: challenges and perspectives for cancer therapy","volume":"14","author":"Lakshmanan","year":"2014","journal-title":"Curr Cancer Drug Targets"},{"key":"18","doi-asserted-by":"publisher","first-page":"27692","DOI":"10.1074\/jbc.M114.592576","article-title":"Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors","volume":"289","author":"Safe","year":"2014","journal-title":"J Biol Chem"},{"key":"19","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3892\/ol.2017.7412","article-title":"Metformin and cancer: An existing drug for cancer prevention and therapy","volume":"15","author":"Cai","year":"2018","journal-title":"Oncol Lett"},{"key":"20","doi-asserted-by":"publisher","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","article-title":"Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells","volume":"67","author":"Sonenberg","year":"2007","journal-title":"Cancer Res"},{"key":"21","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.3892\/ol.2017.7444","article-title":"Metformin synergizes with rapamycin to inhibit the growth of pancreatic cancerand","volume":"15","author":"Sun","year":"2018","journal-title":"Oncol Lett"},{"key":"22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Dodd","year":"2009","journal-title":"Eur J Cancer"},{"key":"23","first-page":"1913","article-title":"Auto-PERCIST: semi-automated response assessment of FDG PET based on PERCIST 1.0 and other criteria","volume":"56","author":"Wahl","year":"2015","journal-title":"J Nucl Med"},{"key":"24","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors","volume":"50","author":"Lodge","year":"2009","journal-title":"J Nucl Med"},{"key":"25","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1016\/j.ejca.2013.06.041","article-title":"Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial","volume":"49","author":"Fugazza","year":"2013","journal-title":"Eur J Cancer"},{"key":"26","doi-asserted-by":"publisher","first-page":"11026","DOI":"10.1038\/srep11026","article-title":"Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis","volume":"5","author":"Zhou","year":"2015","journal-title":"Sci Rep"},{"key":"27","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1634\/theoncologist.2018-0786","article-title":"Long-Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis","volume":"24","author":"de la Fouchardiere","year":"2019","journal-title":"Oncologist"},{"key":"28","doi-asserted-by":"publisher","first-page":"dju413","DOI":"10.1093\/jnci\/dju413","article-title":"nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial","volume":"107","author":"Young","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"29","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.1158\/1078-0432.CCR-18-2992","article-title":"Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)","volume":"25","author":"Crocenzi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"30","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.3748\/wjg.v19.i29.4808","article-title":"FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis","volume":"19","author":"Huang","year":"2013","journal-title":"World J Gastroenterol"},{"key":"31","doi-asserted-by":"publisher","first-page":"e7813","DOI":"10.1097\/MD.0000000000007813","article-title":"Prognostic value of 18F-FDG-PET\/CT parameters in patients with pancreatic carcinoma: A systematic review and meta-analysis","volume":"96","author":"Liao","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"32","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.4049\/jimmunol.1103741","article-title":"Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice","volume":"189","author":"Pearce","year":"2012","journal-title":"J Immunol"},{"key":"33","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.3389\/fimmu.2018.03145","article-title":"Regulation of Dendritic Cell Immune Function and Metabolism by Cellular Nutrient Sensor Mammalian Target of Rapamycin (mTOR)","volume":"9","author":"Amiel","year":"2019","journal-title":"Front Immunol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27586","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,12]],"date-time":"2020-07-12T09:25:52Z","timestamp":1594545952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":33,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2020,5,26]]}},"alternative-id":["27586","32523648"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27586","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,26]]}}}